Based on the Costa Inc stock forecast from 2 analysts, the average analyst target price for Costa Inc is not available over the next 12 months. Costa Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Costa Inc is Very Bearish, which is based on 0 positive signals and 2 negative signals. At the last closing, Costa Inc’s stock price was USD 2,255.28. Costa Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.
No recent analyst target price found for Costa Inc
No recent average analyst rating found for Costa Inc
Company Overview Costa Inc
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. Address: 350 Queen Street, Melbourne, VIC, Australia, 3000 Read Less
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibro...Read More
Frequently Asked Questions About Costa Inc (ATX) Stock
Based on ratings from 2 analysts Costa Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on ATX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ATX is USD 0.00 over the next 12 months. The maximum analyst target price is USD while the minimum anlayst target price is USD .
Unfortunately we do not have enough data on ATX's stock to indicate if its overvalued.
The last closing price of ATX's stock was USD 2,255.28.
The most recent market capitalization for ATX is USD 0.02B.
Based on targets from 2 analysts, the average taret price for ATX is projected at USD 0.00 over the next 12 months.
This means that ATX's stock price may go up by +0.00% over the next 12 months.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ATX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
